Aspirin

Aspirin
Name	Aspirin
Drug class	Nonsteroidal anti-inflammatory drug
Legal status	OTC

Aspirin is a widely used analgesic, antipyretic, and anti-inflammatory medication derived from salicylic acid. It is used for acute pain relief, fever reduction, and long-term prevention of thrombotic cardiovascular events. Developed and commercialized in the late 19th century, it remains on many essential medicines lists and features in public health guidelines worldwide.

Chemistry and pharmacology

Aspirin is acetylsalicylic acid, an acetyl ester of Salicylic acid that belongs to the class of acetylated salicylates and is related to nonsteroidal anti-inflammatory drugs linked in regulatory monographs of agencies such as Food and Drug Administration and European Medicines Agency. Its chemical synthesis historically traces to industrial chemists associated with companies like Bayer AG and techniques developed during the era of organic chemistry advances tied to figures such as Friedrich Bayer and industrialists in Leverkusen. The compound’s physicochemical properties (pKa, solubility, melting point) influence formulation choices used by manufacturers including GlaxoSmithKline and Johnson & Johnson. Analytical methods for quantification employ instrumentation standards from organizations like International Organization for Standardization and analytical chemistry textbooks used in curricula at institutions like Massachusetts Institute of Technology and University of Oxford.

Medical uses

Aspirin is indicated for symptomatic treatment of pain and fever in clinical guidelines from bodies such as the World Health Organization and national agencies including the National Institute for Health and Care Excellence and the American Heart Association. Its antiplatelet properties are recommended for secondary prevention in patients with prior myocardial infarction or ischemic stroke in statements by societies like the European Society of Cardiology and the American College of Cardiology. Use in primary prevention has been debated in trials conducted by consortia including the Women’s Health Study and the Physicians' Health Study, and policy decisions cite work by investigators associated with Harvard University and Johns Hopkins University. Off-label and niche uses have appeared in literature from centers such as Mayo Clinic and Cleveland Clinic.

Adverse effects and contraindications

Common adverse effects include gastrointestinal irritation, peptic ulceration, and bleeding risks noted in meta-analyses from groups like Cochrane Collaboration and reports submitted to regulators such as the Food and Drug Administration. Rare but serious reactions include hypersensitivity syndromes documented in case series from tertiary centers such as Mount Sinai Health System and Massachusetts General Hospital. Contraindications often listed by professional bodies including the American Academy of Pediatrics and Royal College of Physicians include use in children and adolescents with viral infections due to association with Reye syndrome, and avoidance in patients with active peptic ulcer disease described in guidance from National Institute for Health and Care Excellence. Interactions with anticoagulants and antiplatelet drugs have been evaluated in trials led by investigators from Oxford University and reported in journals tied to publishers like Elsevier and Springer Nature.

Mechanism of action

Aspirin irreversibly inhibits cyclooxygenase enzymes (COX-1 and COX-2), a mechanism elucidated in biochemical studies by researchers linked to laboratories at Rockefeller University and University of Cambridge. This acetylation of serine residues reduces prostaglandin and thromboxane synthesis; the thromboxane A2 pathway is central to platelet aggregation discussed in reviews from institutions such as Stanford University and Yale University. The irreversible nature of inhibition underpins recommendations from cardiology guidelines including statements from the American College of Cardiology about dosing intervals and platelet recovery, and mechanistic insights are summarized in monographs used in courses at Columbia University.

Pharmacokinetics

Pharmacokinetic profiles of aspirin—including absorption in the stomach and proximal small intestine, hepatic metabolism to salicylate by esterases, and renal excretion—have been characterized in clinical pharmacology studies from centers like UCSF Medical Center and published in journals associated with societies such as the British Pharmacological Society. Parameters such as half-life and protein binding inform dosing considerations cited in formularies from organizations like the World Health Organization and textbooks used at University of California, San Francisco. Population-specific kinetics, including altered clearance in the elderly and in patients with renal impairment, are described in guidance from National Institutes of Health and specialist texts from Johns Hopkins University.

History and society

The therapeutic use of salicylates dates to traditional practices recorded in archives at institutions such as the British Museum and accounts from physicians like Hippocrates referenced in classical scholarship at University of Cambridge. Modern commercial development in the 1890s by industrial chemists at Bayer AG resulted in large-scale production and trademarking during an era overlapping events like the First World War and the rise of multinational pharmaceutical firms such as Roche and Pfizer. Debates over patent, trademark, and drug naming involved entities like national patent offices and courts including the International Court of Justice in broader intellectual property contexts. Public health campaigns and recommendations by organizations such as the World Health Organization, Centers for Disease Control and Prevention, and national health services have shaped population-level use. Iconic cultural references and biographies of figures in medicine appear in archives at Wellcome Trust and libraries like the Library of Congress.

Formulations and dosage forms

Aspirin is manufactured in multiple dosage forms—immediate-release tablets, enteric-coated tablets, chewable tablets, and effervescent preparations—distributed by companies such as Bayer AG, GlaxoSmithKline, and generic manufacturers listed in procurement catalogs of the World Health Organization. Pediatric and low-dose cardiac preparations are specified in formularies used by institutions including NHS England and hospitals such as Cleveland Clinic. Novel delivery systems and combination products have been investigated in trials from universities like Massachusetts Institute of Technology and University of California, Berkeley and evaluated by regulators including the European Medicines Agency.

Category:Drugs